01—Abstract
Summary
Summary of the 10-K filed February 14, 2024. Cited figures are marked; the original filing is the authoritative source.
Biogen's FY2023 10-K shows a company in transition: total revenue fell 3.3% to $9.84 billiona and diluted EPS dropped 61.8% to $7.97, as multiple sclerosis franchise erosion (MS product revenue down 14.1%, driven by TECFIDERA generics) outpaced growth elsewhere.
Net income attributable to Biogen was $1.16 billionb versus $3.05 billion in 2022, which included a $1.5 billion gain on the Samsung Bioepis sale and a $900 million litigation charge. Results were also affected by roughly $393 million of one-time equity compensation tied to the September 2023 Reata acquisition, $212.5 million of Fit for Growth restructuring charges, and $1.3 billion of SKYCLARYS inventory step-up adjustments flowing through inventory. The balance sheet and capital allocation changed materially.
Biogen spent roughly $6.9 billionc on the Reata acquisition, funded largely from cash and a $1.0 billion term loan. Cash and marketable securities fell from $5.6 billion to $1.0 billion, total borrowings rose to $6.9 billion, and no share repurchases were made in 2023, leaving about $2.1 billion under the authorization. Operating cash flow was $1.55 billion.
Management expects MS revenue to keep declining in 2024, with growth driven by LEQEMBI, SKYCLARYS and the Fit for Growth program, which targets $800 milliond in net operating expense savings by 2025. Key risks include continued generic and biosimilar competition, uncertain LEQEMBI launch economics and reimbursement, IRA drug pricing pressure, an underutilized Solothurn manufacturing plant generating excess-capacity charges, and ongoing litigation including ADUHELM securities actions, a Genentech royalty claim of about $88 million, and government investigations. The company also announced it is exploring strategic options for its biosimilars business.
02—Key points
Key Highlights
- Total revenue declined 3.3% to $9.84B; product revenue fell 9.3% to $7.25B, with MS revenue down 14.1% to $4.66B due to TECFIDERA generic entry
- Diluted EPS fell 61.8% to $7.97 from $20.87, reflecting the absence of the 2022 Samsung Bioepis gain and the 2022 $900M litigation charge, plus 2023 Reata-related charges
- Reata acquisition closed September 26, 2023 for about $6.6B in shares plus $984M in equity awards, adding SKYCLARYS (first EU/US-approved Friedreich's Ataxia drug) and creating a $1.3B inventory step-up and $2.3B IPR&D asset
- Liquidity tightened: cash and marketable securities dropped to $1.05B from $5.6B, borrowings rose to $6.94B, and no buybacks were made in 2023
- Fit for Growth cost program targets approximately $1.0B gross and $800M net operating expense savings by 2025 with about 1,000 net headcount reductions and $260-280M in restructuring charges
- Operating cash flow of $1.55B included $393M of Reata-related equity compensation payments; R&D rose 10.3% to $2.46B, including $125M of trial close-out costs
- Pipeline and launches: LEQEMBI received FDA traditional approval in July 2023 and approval in Japan and China; ZURZUVAE launched for PPD, though a CRL was received for MDD; ADUHELM was discontinued
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 14, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $9.84B$10.17B | −3.3% |
| Cost of Revenue | $2.53B$2.28B | +11.2% |
| Gross Profit | $7.30B$7.90B | −7.5% |
| SG&A Expenses | $2.55B$2.40B | +6.1% |
| Operating Expenses | $8.54B$6.58B | +29.7% |
| Interest Expense | $246.90M$246.60M | +0.1% |
| Net Income | $1.16B$3.05B | −61.9% |
| EPS (Basic) | $8.02$20.96 | −61.7% |
| EPS (Diluted) | $7.97$20.87 | −61.8% |
| Shares Outstanding (Basic) | 144.70M145.30M | −0.4% |
| Shares Outstanding (Diluted) | 145.60M146.00M | −0.3% |
05—Questions
Frequently Asked Questions
Why did Biogen's earnings fall so sharply in 2023?
Diluted EPS fell to $7.97 from $20.87. The 2022 results included a roughly $1.5B pre-tax gain on the sale of the Samsung Bioepis stake and a $503.7M gain on the 125 Broadway building sale, which offset a $900M litigation charge. In 2023, results absorbed about $393M of Reata-related equity compensation, $212.5M of restructuring charges, and higher cost of sales from inventory step-up and idle capacity charges, while MS product sales declined.
How is the Reata acquisition affecting Biogen's financial position?
Biogen paid about $6.6B for Reata shares plus $984M for equity awards, funded by cash on hand and a $1.0B term loan. Cash and marketable securities fell to $1.05B and total borrowings rose to $6.94B. The deal added SKYCLARYS, which generated $55.9M of U.S. revenue in Q4 2023, and roughly $6.5B of intangible assets and goodwill. Management expects continued launch spending and integration costs, and expects higher net interest expense in 2024 due to lower cash balances.
What is the outlook for Biogen's core MS franchise?
Management expects total MS revenue to continue declining in 2024 due to TECFIDERA generic competition in North America, Brazil and parts of the EU, interferon erosion as patients move to higher-efficacy therapies, and a TYSABRI biosimilar that was approved in the U.S. in August 2023 and in the EU in September 2023. Biogen is contesting the EU regulatory protection for TECFIDERA, claiming protection until at least February 2025, but expects generics to remain on the market for some time.
Will Biogen resume share buybacks?
Biogen made no share repurchases in 2023 and about $2.1B remains available under its 2020 program, which has no expiration. The 1% IRA excise tax on net buybacks raises their cost. Management says it continually reviews capital allocation, including dividends, buybacks and acquisitions, and it has not paid cash dividends since inception and has no current intention to do so.
What are the biggest risks flagged in the filing?
Key risks include revenue concentration in MS products facing generic and biosimilar competition, uncertain LEQEMBI and SKYCLARYS launch trajectories and reimbursement, IRA drug price negotiation starting in 2026 for Part D drugs, excess manufacturing capacity at the Solothurn plant, and litigation including the ADUHELM securities actions, a Genentech royalty claim of about $88.3M, a Convergence shareholder suit, and SEC and DOJ subpoenas related to ADUHELM and foreign business operations.
06—Continue